Innovent Biologics announced it will showcase multiple clinical and preclinical results for its obesity and metabolic disease treatments, including mazdutide and next-generation drugs, at the 2026 American Diabetes Association Scientific Sessions. The presentations cover studies on adults and adolescents with obesity and type 2 diabetes, highlighting mazdutide's benefits in weight loss and glycemic control. Innovent also revealed data on new oral GLP-1 receptor agonists and other innovative therapies aimed at improving treatment tolerability and effectiveness. These developments position Innovent as a rising leader in obesity and metabolic disease treatment globally.
Eramet SA disclosed the total number of shares and voting rights as of May 31, 2026. The company has 28,755,047 shares, with theoretical voting rights totaling 49,497,051 and exercisable voting rights at 49,411,630 after accounting for private voting...
Micron Technology CEO Sanjay Mehrotra sold nearly $36 million worth of company stock last week, offloading 37,439 shares at an average price of $960.38 each. This sale was part of a pre-arranged trading plan and reduces his direct holdings by about 8...
The global mobile forensics market is projected to grow from $5.72 billion in 2026 to $9.99 billion by 2031, at an 11.8% CAGR. Growth is fueled by increasing mobile ecosystem complexity, widespread use of encrypted apps, and demand for integrated for...
Costco's stock increased by about 2% following strong May sales results, with net sales up 14.5% year-over-year to $24.01 billion. U.S. comparable sales rose 13.7%, and digitally enabled sales jumped 21.1%, highlighting the company's growing e-commer...
Space stocks are sharply down this week, with Redwire, Momentus, and Rocket Lab falling over 20% due to SpaceX's reduced IPO valuation and a failed short squeeze on Virgin Galactic. SpaceX set its IPO price at $135 per share, valuing the company at $...
